You are here

Article Text

Article menu
Download PDFPDF
Case Reports: Adverse drug reactions and complications
Olaparib-induced cutaneous side effects in a patient with recurrent ovarian cancer
  1. Rei Gou,
  2. Naoki Horikawa and
  3. Kenzo Kosaka
  1. Department of Obstetrics and Gynecology, Shizuoka General Hospital, Shizuoka, Japan
  1. Correspondence to Dr Rei Gou; aoli7755{at}icloud.com

Abstract

Over the past decade, the treatment of ovarian cancer has been revolutionised by poly(ADP-ribose polymerase (PARP)) inhibitors. Based on the results from clinical trials, olaparib, a PARP inhibitor, is indicated for use in the first-line treatment for patients with BRCA gene mutations, and as a maintenance treatment in platinum‐sensitive relapsed ovarian cancer after a complete or partial response to platinum‐based chemotherapy. Although PARP inhibitors have been shown to be well tolerated, adverse side effects can affect the quality of life of patients and lead to the discontinuation of therapy. Here, we report a case of dermatosis of the left dorsal hand as a rare adverse side effect of olaparib. Dermatological adverse side effects may become the crux of a clinical problem that requires the cooperation of professionals in many fields.

  • Obstetrics, gynaecology and fertility
  • Unwanted effects / adverse reactions

https://doi.org/10.1136/bcr-2022-249177

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors RG wrote the manuscript. RG and NH treated the patients and concept the study. KK critical reviewed the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.